DiscGenics reveals positive preclinical results for regenerative spine therapy — 5 takeaways

Written by Megan Wood | March 23, 2018 | Print  |

DiscGenics presented results from two preclinical studies assessing its IDCT product, a homologous, allogenic, injectable cell therapy.

Here are five takeaways.

1. IDCT is a regenerative solution designed for treating mild to moderate degenerative disc disease.

2. The two preclinical studies examined the safety and bioactivity of Discogenic Cells, which are the active ingredient in IDCT. Discogenic Cells are derived from intervertebral disc tissue.

3. The studies implanted the Discogenic Cells in subcutaneous pouches of athymic mice and rabbit disc models.

4. Researchers found Discogenic Cells are safe and non-tumor forming as well as are able to generate intervertebral-like tissue. Additionally, the implantation improved disc height and normalized tissue architecture.

5. The company presented its findings at the Orthopedic Research Society 2018 Annual Meeting, held March 10 to March 13 in New Orleans.

More articles on biologics:
Aziyo Biologics launches OsteGro for spinal fusion, other procedures: 4 insights
Dr. Greg Merrell treats first US patient with Cartiva Synthetic Cartilage Implant for basal joint arthritis: 5 things to know
5 key vendors in the global stem cell therapy market

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months